Best deals to access real time data! |
|
Small Cap Basic
Monthly Subscription
for only
|
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Immune Pharmaceuticals Inc. | IMNPQ | OTCMarkets | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -0.000044 | -1.64% | 0.00264 | 0.0027 | 0.00235 | 0.00235 | 0.002684 | 11:10:47 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 0.0025 | 0.0027 | 0.0002 | 7.41% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 10 | 223,187 | $ 0.002605 | $ 581 | 593,121 | 0.0012 - 0.02 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 11:10:47 | 20,000 | $ 0.00264 | USD |
Immune Pharmaceuticals Inc. Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 427.45k | 181.90M | $ -17.89M | - | - | 36.16M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| 10.89k | $ - | 0.00% | - | - |
Immune Pharmaceuticals Inc. News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IMNPQ Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.0023 | 0.003 | 0.002 | 0.0022694 | 455,021 | 0.00034 | 14.78% |
| 1 Month | 0.0045 | 0.0052 | 0.002 | 0.0032416 | 878,938 | -0.00186 | -41.33% |
| 3 Months | 0.0083 | 0.0086 | 0.002 | 0.0039501 | 542,203 | -0.00566 | -68.19% |
| 6 Months | 0.0046 | 0.0086 | 0.002 | 0.0047011 | 459,296 | -0.00196 | -42.61% |
| 1 Year | 0.0185 | 0.02 | 0.0012 | 0.0058177 | 2,299,994 | -0.01586 | -85.73% |
| 3 Years | 0.16 | 0.17 | 0.0012 | 0.0109016 | 1,833,559 | -0.15736 | -98.35% |
| 5 Years | 0.16 | 0.17 | 0.0012 | 0.0109016 | 1,833,559 | -0.15736 | -98.35% |
Immune Pharmaceuticals Inc. Description
| Immune Pharmaceuticals Inc., together with its subsidiaries (collectively, "Immune" or the "Company" or "us," "we," or "our") is a clinical stage biopharmaceutical company specializing in the development of novel targeted therapeutic agents in the fields of inflammation, dermatology and oncology. Our lead product candidate is bertilimumab, a first-in-class, human, anti-eotaxin-1 antibody that targets eotaxin-1, a key regulator of inflammation. Phase 2 trials of bertilimumab in bullous pemphigoid ("BP"), our lead indication, as well as in allergic rhinitis and allergic conjunctivitis, have been completed, and a phase 2 clinical trial in ulcerative colitis ("UC") has completed recruiting subjects, although this trial remains blinded. We are also developing a nano-encapsulated topical formulation of cyclosporine-A, which we refer to as "NanoCyclo," for the treatment of atopic dermatitis ("AD") and psoriasis. We also own certain rights to Ceplene, which is approved in the European Union for the maintenance of remission in patients with Acute Myeloid Leukemia ("AML") in combination with interleukin-2 (IL-2). |
